{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:45:40Z","timestamp":1770684340863,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Oncology Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.oor.2024.100228","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T03:56:27Z","timestamp":1708574187000},"page":"100228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ibrutinib-associated osteonecrosis of the jaw"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-4492","authenticated-orcid":false,"given":"Annu","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8902-6503","authenticated-orcid":false,"given":"Sion","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-6264","authenticated-orcid":false,"given":"Joseph M.","family":"Huryn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherry L.","family":"Estilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-7569","authenticated-orcid":false,"given":"SaeHee K.","family":"Yom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.oor.2024.100228_bib1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and Maxillofacial Surgeons. American association of oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"10.1016\/j.oor.2024.100228_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management","volume":"102","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.oor.2024.100228_bib3","first-page":"c85","article-title":"Physiology and pharmacology of nonbisphopshonate drugs implicated in osteonecrosis of the jaw","volume":"78","author":"Troeltzsch","year":"2012","journal-title":"J Can Dent Assoc"},{"issue":"4","key":"10.1016\/j.oor.2024.100228_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"10.1016\/j.oor.2024.100228_bib5","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.oor.2024.100228_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5125\/jkaoms.2019.45.1.3","article-title":"Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology","volume":"45","author":"Nifos\u00ec","year":"2019","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.oor.2024.100228_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10006-020-00913-z","article-title":"Osteonecrosis of the jaws associated with protein kinase inhibitors: a systematic review","volume":"25","author":"Mian","year":"2021","journal-title":"Oral Maxillofac Surg"},{"issue":"24","key":"10.1016\/j.oor.2024.100228_bib8","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.oor.2024.100228_bib9","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.oraloncology.2015.08.014","article-title":"Osteonecrosis of the jaw a new complication related to Ipilimumab","volume":"51","author":"Owosho","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oor.2024.100228_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105660","article-title":"Ramucirumab-related osteonecrosis of the jaw","volume":"125","author":"Singh","year":"2022","journal-title":"Oral Oncol"},{"issue":"4","key":"10.1016\/j.oor.2024.100228_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.oor.2024.100228_bib12","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated Mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.oor.2024.100228_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae Insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 3.2022","volume":"20","author":"Wierda","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.oor.2024.100228_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.oor.2024.100228_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oor.2024.100228_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative Analysis of BTK inhibitors and Mechanisms Underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.oor.2024.100228_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000497356","article-title":"Five ibrutinib-associated side effects that All Clinicians Should Be aware of","volume":"141","author":"Levy","year":"2019","journal-title":"Acta Haematol"},{"key":"10.1016\/j.oor.2024.100228_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.oor.2024.100228_bib19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.oor.2024.100228_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.15620","article-title":"Dose-limiting stomatitis associated with ibrutinib therapy: a case series","volume":"185","author":"Vigarios","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Oral Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772906024000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772906024000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:37:33Z","timestamp":1770622653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772906024000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"alternative-id":["S2772906024000748"],"URL":"https:\/\/doi.org\/10.1016\/j.oor.2024.100228","relation":{},"ISSN":["2772-9060"],"issn-type":[{"value":"2772-9060","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib-associated osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Oral Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oor.2024.100228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100228"}}